Terms: = Colorectal cancer AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1
590 results:
1. Biomarkers to predict efficacy of immune checkpoint inhibitors in colorectal cancer patients: a systematic review and meta-analysis.
Yu H; Liu Q; Wu K; Tang S
Clin Exp Med; 2024 Jul; 24(1):143. PubMed ID: 38960935
[TBL] [Abstract] [Full Text] [Related]
2. Tumor Infiltrating Effector Regulatory T Cells Express VEGF Receptor 2 in Patients With colorectal cancer.
Tsumuraya H; Mimura K; Nakajima S; Hanayama H; Matsuishi A; Okayama H; Fukai S; Ito M; Ashizawa M; Chida S; Onozawa H; Sakamoto W; Saito M; Saze Z; Momma T; Kono K
Anticancer Res; 2024 Jul; 44(7):2933-2941. PubMed ID: 38925828
[TBL] [Abstract] [Full Text] [Related]
3. Fruquintinib-induced renal-limited thrombotic microangiopathy: a case report.
Zhao R; Fan R; Pan Y; Han Y; Wang Y; Chen W
BMC Nephrol; 2024 May; 25(1):170. PubMed ID: 38762494
[TBL] [Abstract] [Full Text] [Related]
4. Meroterpenoids from Marine Sponge
Wang J; Yan YL; Yu XY; Pan JY; Liu XL; Hong LL; Wang B
Mar Drugs; 2024 Apr; 22(4):. PubMed ID: 38667800
[TBL] [Abstract] [Full Text] [Related]
5. Anti-vegfr2-Interferon α Promotes the Infiltration of CD8+ T Cells in colorectal cancer by Upregulating the Expression of CCL5.
Huang L; Gao R; Nan L; Qi J; Yang S; Shao S; Xie J; Pan M; Qiu T; Zhang J
J Immunother; 2024 Jul-Aug 01; 47(6):195-204. PubMed ID: 38654631
[TBL] [Abstract] [Full Text] [Related]
6. Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence?
Stucchi E; Bartolini M; Airoldi M; Fazio R; Daprà V; Mondello G; Prete MG; Puccini A; Santoro A
Expert Opin Pharmacother; 2024 Mar; 25(4):371-382. PubMed ID: 38568032
[TBL] [Abstract] [Full Text] [Related]
7. Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness.
Mongiardi MP; Pallini R; D'Alessandris QG; Levi A; Falchetti ML
Expert Rev Mol Med; 2024 Apr; 26():e5. PubMed ID: 38563164
[TBL] [Abstract] [Full Text] [Related]
8. Metabolism, toxicity and management of fruquintinib: a novel drug for metastatic colorectal cancer.
Patell K; Mears VL; Storandt MH; Mahipal A
Expert Opin Drug Metab Toxicol; 2024 Apr; 20(4):197-205. PubMed ID: 38497279
[TBL] [Abstract] [Full Text] [Related]
9. Magnetic resonance imaging-based approaches for detecting the efficacy of combining therapy following vegfr-2 and PD-1 blockade in a colon cancer model.
Xu X; Ma M; Ye K; Zhang D; Chen X; Wu J; Mo X; Xiao Z; Shi C; Luo L
J Transl Med; 2024 Feb; 22(1):198. PubMed ID: 38395884
[TBL] [Abstract] [Full Text] [Related]
10. Ethyl cinnamate suppresses tumor growth through anti-angiogenesis by attenuating vegfr2 signal pathway in colorectal cancer.
Wang S; Yang J; Kuang X; Li H; Du H; Wu Y; Xu F; Liu B
J Ethnopharmacol; 2024 May; 326():117913. PubMed ID: 38360380
[TBL] [Abstract] [Full Text] [Related]
11. Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer.
Arai H; Yang Y; Baca Y; Millstein J; Denda T; Ou FS; Innocenti F; Takeda H; Kubota Y; Doi A; Horie Y; Umemoto K; Izawa N; Wang J; Battaglin F; Jayachandran P; Algaze S; Soni S; Zhang W; Goldberg RM; Hall MJ; Scott AJ; Hwang JJ; Lou E; Weinberg BA; Marshall J; Goel S; Xiu J; Michael Korn W; Venook AP; Sunakawa Y; Lenz HJ
Eur J Cancer; 2024 Apr; 201():113914. PubMed ID: 38359495
[TBL] [Abstract] [Full Text] [Related]
12. Effects of total coumarins from
Liu Y; Cheng DH; Su ZY; Lv JH; Wang L; Deng YY; Li L
Pharm Biol; 2024 Dec; 62(1):153-161. PubMed ID: 38347502
[TBL] [Abstract] [Full Text] [Related]
13. Design, synthesis, and anticancer evaluation of N-sulfonylpiperidines as potential vegfr-2 inhibitors, apoptotic inducers.
Elgammal WE; Halawa AH; Eissa IH; Elkady H; Metwaly AM; Hassan SM; El-Agrody AM
Bioorg Chem; 2024 Apr; 145():107157. PubMed ID: 38340473
[TBL] [Abstract] [Full Text] [Related]
14. Challenging the anticolorectal cancer capacity of quinoxaline-based scaffold via triazole ligation unveiled new efficient dual vegfr-2/MAO-B inhibitors.
Ayoup MS; Ammar A; Abdel-Hamid H; Amer A; Abu-Serie MM; Nasr SA; Ghareeb DA; Teleb M; Tageldin GN
Bioorg Chem; 2024 Feb; 143():107102. PubMed ID: 38211551
[TBL] [Abstract] [Full Text] [Related]
15. Glucagon Enhances Chemotherapy Efficacy By Inhibition of Tumor Vessels in colorectal cancer.
Xu Y; Ni F; Sun D; Peng Y; Zhao Y; Wu X; Li S; Qi X; He X; Li M; Zhou Y; Zhang C; Yan M; Yao C; Zhu S; Yang Y; An B; Yang C; Zhang G; Jiang W; Mi J; Chen X; Wei P; Tian G; Zhang Y
Adv Sci (Weinh); 2024 Feb; 11(6):e2307271. PubMed ID: 38072640
[TBL] [Abstract] [Full Text] [Related]
16. Zinc supplementation decreased incidence of grade ≥2 hand-foot skin reaction induced by regorafenib: A phase II randomized clinical trial.
Huang WK; Hsu HC; Yang TS; Lu CW; Pan YR; Wu CE; Chung WH; Hung SI; Yeh CN
Eur J Cancer; 2023 Dec; 195():113286. PubMed ID: 37968194
[TBL] [Abstract] [Full Text] [Related]
17. Low EGFL7 expression is associated with high lymph node spread and invasion of lymphatic vessels in colorectal cancer.
de Oliveira C; Martins SFF; Gonçalves PG; Limone GA; Longatto-Filho A; Reis RM; Bidinotto LT
Sci Rep; 2023 Nov; 13(1):19783. PubMed ID: 37957249
[TBL] [Abstract] [Full Text] [Related]
18. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
Sohel M
Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
[TBL] [Abstract] [Full Text] [Related]
19. Novel 3-phenylquinazolin-2,4(1H,3H)-diones as dual vegfr-2/c-Met-TK inhibitors: design, synthesis, and biological evaluation.
Hassan A; Mosallam AM; Ibrahim AOA; Badr M; Abdelmonsef AH
Sci Rep; 2023 Oct; 13(1):18567. PubMed ID: 37903949
[TBL] [Abstract] [Full Text] [Related]
20. Antitumor activity of the new tyrphostin briva against BRAF
Saleh K; Al Sakhen M; Kanaan S; Yasin S; Höpfner M; Tahtamouni L; Biersack B
Invest New Drugs; 2023 Dec; 41(6):791-801. PubMed ID: 37870738
[TBL] [Abstract] [Full Text] [Related]
[Next]
